IN8bio, Inc. Form 8-K Summary
Business Context and Reporting Period
IN8bio, Inc. filed a Current Report on Form 8-K dated September 10, 2021, under Items 2.02 and 9.01. The filing references the company’s financial results for the quarter ended June 30, 2021. IN8bio is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol INAB.
Financial Metrics
The filing states that a press release announcing quarterly financial results was furnished as Exhibit 99.1, but the provided filing text does not include the press release or its financial figures. Revenue, net loss, cash flow, margins, debt, liquidity, cash balance, and other key metrics are therefore not clearly provided.
Material Changes Versus the Prior Comparable Period
The filing text does not provide quantitative or qualitative comparisons with the prior-year quarter or immediately preceding period.
Guidance, Outlook, Risks, and Unusual Items
No guidance, forecast, management outlook, risk discussion, contingencies, or unusual items are included in the provided text. The referenced Exhibit 99.1 may contain additional management commentary and financial information, but it is not included here.
Important Facts to Verify
- Obtain and review Exhibit 99.1 for the quarter ended June 30, 2021, including revenue, operating expenses, net loss, cash position, and cash runway.
- Verify comparative results and any changes in liquidity, financing, debt, or capital resources.
- Review management’s discussion of clinical development programs, milestones, risks, and forward-looking expectations, if included in the press release.
- Note that the information in the Form 8-K and Exhibit 99.1 was furnished, not filed for purposes of Section 18 of the Exchange Act, and is not incorporated by reference except where expressly stated.